This company listing is no longer active
Genocea Biosciences Balance Sheet Health
Financial Health criteria checks 3/6
Genocea Biosciences has a total shareholder equity of $12.4M and total debt of $7.6M, which brings its debt-to-equity ratio to 61.7%. Its total assets and total liabilities are $38.8M and $26.4M respectively.
Key information
61.7%
Debt to equity ratio
US$7.65m
Debt
| Interest coverage ratio | n/a |
| Cash | US$20.14m |
| Equity | US$12.39m |
| Total liabilities | US$26.40m |
| Total assets | US$38.79m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0A51's short term assets ($24.4M) exceed its short term liabilities ($18.0M).
Long Term Liabilities: 0A51's short term assets ($24.4M) exceed its long term liabilities ($8.4M).
Debt to Equity History and Analysis
Debt Level: 0A51 has more cash than its total debt.
Reducing Debt: 0A51's debt to equity ratio has increased from 51.6% to 61.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 0A51 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0A51 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.